Investor Overview
NEW - - - SKVI Now Trading Exclusively on OTCQB
Beginning February 22, 2011 Skinvisible (SKVI) will be quoted exclusively on the new OTCQB www.otcmarkets.com with an icon reading, "OTCQB -- U.S. Registered."
This new designation is used for OTC-traded companies that are U.S. registered and reporting. The OTCQB will help investors easily identify SEC reporting companies such as Skinvisible that are current with their disclosure obligations. As of February 18, 2011, market makers that previously traded Skinvisible on the OTCBB began exclusively trading Skinvisible on the new OTCQB. We do not believe it necessary at this time to reapply for quotation on the OTCBB because of the new trend in trading on the OTCQB.
To get a SKVI quote today, click here:
http://www.otcmarkets.com/stock/SKVI/quote
IMPORTANT: The OTCQB inter-dealer quotation system is interlinked with most financial websites but we encourage you to look at other sites if you do not see a current quote. All financial websites should be up-to-date in the near future.
Shareholder's Information:
Shares Outstanding Are: 109,750,409
Authorized: 200,000,000
Public Float: 55%
Insider Ownership: 45%
Fiscal Year End: December 31, 2012
December 4, 2012
Skinvisible Granted US Patent for Topical Drug Delivery Technology
- Invisicare® Patent Protection Extends to Year 2029
November 27, 2012
Skinvisible Granted US Patent for Stabilizing Retinoids
- Intellectual Property Portfolio Strengthens
June 28, 2012
Skinvisible's Hand Sanitizer Kills "Super Bug" MRSA and E. coli For Up to 4 Hours
- Studies Confirm One Application of DermSafe As An Effective Long-Lasting Hand Sanitizer
April 12, 2012
Skinvisible Licensee Increases US Sales for Women's Health Product Made with Invisicare
- ProCort® Distribution Expands to Puerto Rico
March 7, 2012
Skinvisible Granted US Sunscreen Patent for UVA Absorber
- Broad Spectrum UVA / UVB Sunscreens with Invisicare Offer Eight Hours of Photostability
February 23, 2012
Skinvisible Formulation Submitted to European Union for Orphan Drug Designation
- Invisicare Formulation for Netherton Syndrome Under Review
CLICK HERE TO READ ALL NEWS RELEASES
|
In the News:
Skinvisible featured in Drug Development & Delivery journal
Stock Information:
SKVI quote
Press Releases
Skinvisible Shareholder Update: 2012 in Review
Sign up for Skinvisible Inc. Updates:
Click here to join our mailing list.
|
Skinvisible Web
PDF - 445k)